AP519A - Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflamatory diseases. - Google Patents

Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflamatory diseases. Download PDF

Info

Publication number
AP519A
AP519A APAP/P/1996/000794A AP9600794A AP519A AP 519 A AP519 A AP 519A AP 9600794 A AP9600794 A AP 9600794A AP 519 A AP519 A AP 519A
Authority
AP
ARIPO
Prior art keywords
cyano
methoxyphenyl
cyclohexane
methyl
cyclopropylmethoxy
Prior art date
Application number
APAP/P/1996/000794A
Other languages
English (en)
Other versions
AP9600794A0 (en
Inventor
Siegfried Benjamin Christensen
Original Assignee
Smithkline Beecham Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from SG1996007903A external-priority patent/SG47107A1/en
Application filed by Smithkline Beecham Corp filed Critical Smithkline Beecham Corp
Publication of AP9600794A0 publication Critical patent/AP9600794A0/xx
Application granted granted Critical
Publication of AP519A publication Critical patent/AP519A/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D257/00—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms
    • C07D257/02—Heterocyclic compounds containing rings having four nitrogen atoms as the only ring hetero atoms not condensed with other rings
    • C07D257/04—Five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C255/00—Carboxylic acid nitriles
    • C07C255/45—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C07C255/46—Carboxylic acid nitriles having cyano groups bound to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of non-condensed rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C259/00—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups
    • C07C259/04—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids
    • C07C259/08—Compounds containing carboxyl groups, an oxygen atom of a carboxyl group being replaced by a nitrogen atom, this nitrogen atom being further bound to an oxygen atom and not being part of nitro or nitroso groups without replacement of the other oxygen atom of the carboxyl group, e.g. hydroxamic acids having carbon atoms of hydroxamic groups bound to carbon atoms of rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C323/00—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups
    • C07C323/50—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton
    • C07C323/51—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton
    • C07C323/60—Thiols, sulfides, hydropolysulfides or polysulfides substituted by halogen, oxygen or nitrogen atoms, or by sulfur atoms not being part of thio groups containing thio groups and carboxyl groups bound to the same carbon skeleton having the sulfur atoms of the thio groups bound to acyclic carbon atoms of the carbon skeleton with the carbon atom of at least one of the carboxyl groups bound to nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/06—1,2,4-Oxadiazoles; Hydrogenated 1,2,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D271/00—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms
    • C07D271/02—Heterocyclic compounds containing five-membered rings having two nitrogen atoms and one oxygen atom as the only ring hetero atoms not condensed with other rings
    • C07D271/10—1,3,4-Oxadiazoles; Hydrogenated 1,3,4-oxadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D285/00—Heterocyclic compounds containing rings having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by groups C07D275/00 - C07D283/00
    • C07D285/01—Five-membered rings
    • C07D285/02—Thiadiazoles; Hydrogenated thiadiazoles
    • C07D285/04—Thiadiazoles; Hydrogenated thiadiazoles not condensed with other rings
    • C07D285/12—1,3,4-Thiadiazoles; Hydrogenated 1,3,4-thiadiazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/02—Systems containing only non-condensed rings with a three-membered ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/14—The ring being saturated
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/12—Systems containing only non-condensed rings with a six-membered ring
    • C07C2601/16—Systems containing only non-condensed rings with a six-membered ring the ring being unsaturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
APAP/P/1996/000794A 1992-04-02 1993-03-30 Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflamatory diseases. AP519A (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US86203092A 1992-04-02 1992-04-02
US96876292A 1992-10-30 1992-10-30
SG1996007903A SG47107A1 (en) 1992-04-02 1993-03-05 Compounds useful for treating allergic and inflammatory diseases
PCT/US1993/001991 WO1993019749A1 (en) 1992-04-02 1993-03-05 Compounds useful for treating allergic and inflammatory diseases

Publications (2)

Publication Number Publication Date
AP9600794A0 AP9600794A0 (en) 1996-04-30
AP519A true AP519A (en) 1996-08-23

Family

ID=27356137

Family Applications (2)

Application Number Title Priority Date Filing Date
APAP/P/1993/000508A AP516A (en) 1992-04-02 1993-03-30 Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflammatory diseases.
APAP/P/1996/000794A AP519A (en) 1992-04-02 1993-03-30 Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflamatory diseases.

Family Applications Before (1)

Application Number Title Priority Date Filing Date
APAP/P/1993/000508A AP516A (en) 1992-04-02 1993-03-30 Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflammatory diseases.

Country Status (18)

Country Link
US (4) US5552438A (sl)
EP (1) EP0633776B1 (sl)
CN (1) CN1066436C (sl)
AP (2) AP516A (sl)
AU (1) AU677776B2 (sl)
BG (1) BG62235B1 (sl)
CA (1) CA2133439C (sl)
CZ (1) CZ283425B6 (sl)
FI (1) FI944549A (sl)
GR (1) GR3036347T3 (sl)
HU (1) HU225869B1 (sl)
IL (1) IL105221A (sl)
MX (1) MX9301943A (sl)
NO (1) NO303116B1 (sl)
NZ (1) NZ251092A (sl)
SI (1) SI9300169B (sl)
SK (1) SK279958B6 (sl)
WO (1) WO1993019749A1 (sl)

Families Citing this family (240)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SI0710109T1 (sl) * 1993-06-18 2005-02-28 Smithkline Beecham Corporation Metoda za identificiranje PDE IV-inhibitorja
GB9312853D0 (en) 1993-06-22 1993-08-04 Euro Celtique Sa Chemical compounds
JPH09501420A (ja) * 1993-07-30 1997-02-10 スミスクライン・ビーチャム・コーポレイション ３−シアノ−３−（３，４−二置換）フェニルシクロヘキシル−１−カルボキシレート類
GB9404706D0 (en) * 1994-03-11 1994-04-27 Smithkline Beecham Corp Compounds
US6013827A (en) * 1994-03-11 2000-01-11 Smithkline Beecham Corporation Compounds
US20060019963A1 (en) * 1994-06-17 2006-01-26 Smithkline Beecham Corporation Compounds
US5998428A (en) * 1995-05-31 1999-12-07 Smithkline Beecham Corporation Compounds and methods for treating PDE IV-related diseases
US5591776A (en) * 1994-06-24 1997-01-07 Euro-Celtique, S.A. Pheynl or benzyl-substituted rolipram-based compounds for and method of inhibiting phosphodiesterase IV
US5922751A (en) 1994-06-24 1999-07-13 Euro-Celtique, S.A. Aryl pyrazole compound for inhibiting phosphodiesterase IV and methods of using same
JPH10511392A (ja) * 1994-12-23 1998-11-04 スミスクライン・ビーチャム・コーポレイション ４，４−（二置換）シクロヘキサン−１−カルボキシレートダイマーおよび関連化合物
WO1996019994A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation 3,3-(disubstituted)cyclohexan-1-carboxylate monomers and related compounds
JPH10511398A (ja) * 1994-12-23 1998-11-04 スミスクライン・ビーチャム・コーポレイション ４，４−（二置換）シクロヘキサン−１−カルボキシレート単量体および関連する化合物
WO1996020156A1 (en) * 1994-12-23 1996-07-04 Smithkline Beecham Corporation 3,3-(disubstituted)cyclohexan-1-carboxylate dimers and related compounds
EP0799182A4 (en) * 1994-12-23 1998-03-25 Smithkline Beecham Corp DIMERES 3.3- (DISUBSTITUTED) CYCLOHEXAN-1-OL AND RELATED COMPOUNDS
WO1996036626A1 (de) * 1995-05-18 1996-11-21 Byk Gulden Lomberg Chemische Fabrik Gmbh Cyclohexyldihydrobenzofurane
ATE231501T1 (de) * 1995-05-18 2003-02-15 Altana Pharma Ag Phenyldihydrobenzofurane
US6166041A (en) 1995-10-11 2000-12-26 Euro-Celtique, S.A. 2-heteroaryl and 2-heterocyclic benzoxazoles as PDE IV inhibitors for the treatment of asthma
US5891883A (en) * 1995-12-21 1999-04-06 Smithkline Beecham Corporation 4,4-(disubstituted)cyclohexan-1-ols monomers and related compounds
US6075016A (en) 1996-04-10 2000-06-13 Euro-Celtique S.A. 6,5-fused aromatic ring systems having enhanced phosphodiesterase IV inhibitory activity
AP2001002304A0 (en) * 1996-05-03 2001-12-31 Pfizer Substituted indazole derivatives and related compounds
JP4373497B2 (ja) 1996-06-19 2009-11-25 ローン−プーラン・ロレ・リミテツド 置換されたアザビシクロ化合物、ならびにｔｎｆおよびサイクリックａｍｐホスホジエステラーゼ産生の阻害剤としてのそれらの使用
BR9712782A (pt) * 1996-06-25 1999-12-07 Pfizer Derivados de indazol substituìdo e seu uso como inibidores de fosfodiesterose (pde) e fator de necrose de tumor (tnf)
EP0941221B1 (en) * 1996-11-20 2003-02-26 ALTANA Pharma AG Substituted dihydrobenzofurans as pde inhibitors
MY118813A (en) 1997-02-12 2005-01-31 Smithkline Beecham Corp Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
EP1327627A1 (en) * 1997-02-12 2003-07-16 SmithKline Beecham Corporation Compounds and method for preparing substituted 4-phenyl-4-cyanocyclohexanoic acids
EP1524268B1 (en) * 1997-02-12 2007-01-17 Smithkline Beecham Corporation Compounds and method for preparing sustituted 4-phenyl-4-cyanocyclohexanoic acids
UA67753C2 (uk) * 1997-10-10 2004-07-15 Смітклайн Бічам Корпорейшн Спосіб отримання заміщених 4-феніл-4-ціанциклогексанових кислот
UY25338A1 (es) * 1998-01-07 2001-08-27 Smithkline Beecham Corp Método para tratar copd
AU2026299A (en) * 1998-01-07 1999-07-26 Smithkline Beecham Corporation Method for treating multiple sclerosis
US6172118B1 (en) * 1998-04-14 2001-01-09 Smithkline Beecham Corporation Compounds
US6395273B1 (en) 1998-06-10 2002-05-28 Promega Corporation Prevention and treatment of inflammatory bowel disease
US7906481B2 (en) * 1998-09-25 2011-03-15 Sciaticon Ab Specific TNF-A inhibitors for treating spinal disorders mediated by nucleous pulposus
US7811990B2 (en) * 1998-09-25 2010-10-12 Sciaticon Ab Soluble cytokine receptors TNF-α blocking antibodies for treating spinal disorders mediated by nucleus pulposus
US7115557B2 (en) * 1998-09-25 2006-10-03 Sciaticon Ab Use of certain drugs for treating nerve root injury
SE9803710L (sv) * 1998-09-25 2000-03-26 A & Science Invest Ab Användning av vissa substanser för behandling av nervrotsskador
RU2235095C2 (ru) 1998-10-06 2004-08-27 Дайниппон Фармасьютикал Ко., Лтд. 2,3-дизамещенное производное пиридина, способы его получения, содержащая его фармацевтическая композиция и промежуточный продукт для его получения
MY121142A (en) * 1999-02-23 2005-12-30 Smithkline Beecham Corp Controlled release formulation for treating copd
US6419934B1 (en) * 1999-02-24 2002-07-16 Edward L. Tobinick TNF modulators for treating neurological disorders associated with viral infection
AR035987A1 (es) * 1999-03-01 2004-08-04 Smithkline Beecham Corp Uso de un compuesto inhibidor de la pde 4 para la manufactura de un medicamento y el medicamento para tratar asma inducida por ejercicio
DZ3019A1 (fr) * 1999-03-01 2005-05-20 Smithkline Beecham Corp Utilisation d'un inhibiteur de pde4 dans la préparation d'un médicament contre la copd.
ATE277903T1 (de) * 1999-05-14 2004-10-15 Bristol Myers Squibb Pharma Re Zyklische aminderivate und ihre verwendung
AR024076A1 (es) * 1999-05-25 2002-09-04 Smithkline Beecham Corp Sales de cis-[4-ciano-4-(3-ciclopentiloxi-4-metoxifenil) ciclohexan-1-carboxilato]
ECSP003599A (es) * 1999-08-06 2002-03-25 Smithkline Beecham Corp Procedimiento para preparar acidos a traves de alfa-coroepoxi-esteres
US6740765B1 (en) * 1999-08-06 2004-05-25 Smithkline Beecham Corporation Method for preparing cyclohexane carboxylic acids
US20040220424A1 (en) * 1999-08-06 2004-11-04 Smithkline Beecham Corporation Process for preparing acids via alpha-chloroepoxy esters
US6296840B1 (en) * 1999-08-06 2001-10-02 Rodan & Fields, Llc Masque
PT1212089E (pt) 1999-08-21 2006-08-31 Altana Pharma Ag Combinacao sinergica de roflumilast e salmeterol
UY26333A1 (es) * 1999-09-15 2001-07-31 Smithkline Beecham Corp Procedimiento e intermedios para preparar ácidos (4-ciano sustituido)- ciclohexanoicos
US20030050497A1 (en) * 2002-07-11 2003-03-13 Webb Kevin Scott Process and intermediates for preparing a cyclohexylnitrile
AR029788A1 (es) * 2000-01-12 2003-07-16 Smithkline Beecham Corp Procedimiento para reducir acidos ciclohexeno carboxilicos alfa,beta-insaturados, procedimiento para preparar acidos 4-nitrilo-4-aril-ciclohexanoicos, procedimiento para preparar acidos ciclohexeno carboxilicos alfa,beta-insaturados, y procedimientos para preparar intermediarios
BR0107709A (pt) * 2000-01-26 2002-11-19 Smithkline Beecham Corp Monoidrato de cis-litio 4-ciano-4-[ 3-( ciclopentiloxi )-4-metoxifenil ] ciclohexanocarboxilato
AU7205701A (en) * 2000-02-08 2001-08-20 Smithkline Beecham Corporation Method and compositions for treating an inflammatory disease
WO2001060358A1 (en) * 2000-02-16 2001-08-23 University Of Nebraska Medical Center Method and compositions for treating fibrotic diseases
EP1265861A2 (en) 2000-03-16 2002-12-18 Inflazyme Pharmaceuticals, Ltd. Benzylated pde4 inhibitors
GB0011802D0 (en) * 2000-05-16 2000-07-05 Smithkline Beecham Method for enhancing cognitive function
US20040005995A1 (en) * 2001-07-26 2004-01-08 Edelson Jeffrey D Method for reducing exacerbations associated with copd
BRPI0113042B8 (pt) 2000-08-05 2021-05-25 Glaxo Group Ltd composto da fórmula ou um seu solvato fisiologicamente aceitável, uso do mesmo, composição farmacêutica, formulação farmacêutica, método para o tratamento de um indivíduo humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para preparar um composto ou um seu solvato
US20040224316A1 (en) 2000-08-10 2004-11-11 Tully Timothy P. Augmented cognitive training
US7250518B2 (en) * 2001-01-31 2007-07-31 Pfizer Inc. Nicotinamide acids, amides, and their mimetics active as inhibitors of PDE4 isozymes
IL156460A0 (en) * 2001-01-31 2004-01-04 Pfizer Prod Inc Ether derivatives useful as inhibitors of pde4 isozymes
JP2004520386A (ja) 2001-01-31 2004-07-08 ファイザー・プロダクツ・インク Ｐｄｅ４アイソザイムの阻害剤として有用なニコチンアミドビアリール誘導体
BR0116850A (pt) * 2001-01-31 2004-02-25 Pfizer Prod Inc Derivados de amida de ácido tiazolil-, oxazolil-, pirrolil- e imidazolil- úteis como inibidores de isoenzimas de pde4
GB0103630D0 (en) * 2001-02-14 2001-03-28 Glaxo Group Ltd Chemical compounds
ES2296923T3 (es) * 2001-03-22 2008-05-01 Glaxo Group Limited Derivados formanilidas como agonistas del adrenorreceptor beta2.
BR0209271A (pt) 2001-04-30 2004-06-15 Glaxo Group Ltd Composto, uso de um composto composição farmacêutica, formulação em aerossol farmacêutica, método para o tratamento de um paciente humano ou animal com uma condição inflamatória e/ou alérgica, e, processo para a preparação de um composto
MXPA03010679A (es) * 2001-05-23 2004-03-02 Tanabe Seiyaku Co Una composicion para acelerar la cicatrizacion de fractura osea.
CA2447618A1 (en) * 2001-05-23 2002-11-28 Tanabe Seiyaku Co., Ltd. A composition for regenerative treatment of cartilage disease
USRE44874E1 (en) * 2001-09-14 2014-04-29 Glaxo Group Limited Phenethanolamine derivatives for treatment of respiratory diseases
GB0201677D0 (en) 2002-01-25 2002-03-13 Glaxo Group Ltd Medicament dispenser
GB0217199D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
CN1649614A (zh) 2002-02-22 2005-08-03 新河药品股份有限公司 活性剂传递系统和保护及施用活性剂的方法
GB0204719D0 (en) * 2002-02-28 2002-04-17 Glaxo Group Ltd Medicinal compounds
AU2003222841A1 (en) * 2002-04-25 2003-11-10 Glaxo Group Limited Phenethanolamine derivatives
US20030013905A1 (en) * 2002-06-10 2003-01-16 Huang Guishu Kris Salts of cis-4-cyano-4[3(cyclopentyloxy)-4-methoxyphenyl]cyclohexane-1-carboxylic acid
GB0217198D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
GB0217225D0 (en) 2002-07-25 2002-09-04 Glaxo Group Ltd Medicinal compounds
GB0217196D0 (en) * 2002-07-25 2002-09-04 Glaxo Group Ltd Medicament dispenser
ES2291733T3 (es) * 2002-10-22 2008-03-01 Glaxo Group Limited Compuestos de ariletanolamina medicinales.
SI1556342T1 (sl) 2002-10-28 2008-08-31 Glaxo Group Ltd Fenetanolaminski derivat za zdravljenje respiratornih bolezni
US20060040981A1 (en) * 2002-11-22 2006-02-23 Daniel Dube Use of phosphodiesterase-4 inhibitors as enhancers of cognition
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
GB0303396D0 (en) * 2003-02-14 2003-03-19 Glaxo Group Ltd Medicinal compounds
JP2006522151A (ja) 2003-04-01 2006-09-28 アプライド リサーチ システムズ エーアールエス ホールディング ナームロゼ フェンノートシャップ 不妊症におけるホスホジエステラーゼ阻害剤
WO2005002626A2 (en) * 2003-04-25 2005-01-13 Gilead Sciences, Inc. Therapeutic phosphonate compounds
WO2004098578A2 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and a tnf-alfa antagonist selected from infliximab, adalimumab, cdp870 and cdp517
WO2004098606A1 (en) * 2003-05-12 2004-11-18 Altana Pharma Ag Composition comprising a pde4 inhibitor and shuil-1r ii
JP4901474B2 (ja) 2003-05-30 2012-03-21 ランバクシー ラボラトリーズ リミテッド 置換ピロール誘導体
GB0316290D0 (en) 2003-07-11 2003-08-13 Glaxo Group Ltd Novel compounds
DE10331798B4 (de) * 2003-07-14 2012-06-21 Giesecke & Devrient Gmbh Sicherheitselement, Wertgegenstand, Transfermaterial und Herstellungsverfahren
GB0317374D0 (en) 2003-07-24 2003-08-27 Glaxo Group Ltd Medicament dispenser
US20050085430A1 (en) * 2003-07-31 2005-04-21 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20050026883A1 (en) * 2003-07-31 2005-02-03 Robinson Cynthia B. Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a PDE-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
US20090274676A1 (en) * 2003-07-31 2009-11-05 Robinson Cynthia B Combination of dehydroepiandrosterone or dehydroepiandrosterone-sulfate with a pde-4 inhibitor for treatment of asthma or chronic obstructive pulmonary disease
GB0324654D0 (en) * 2003-10-22 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0324886D0 (en) * 2003-10-24 2003-11-26 Glaxo Group Ltd Medicinal compounds
GB0401334D0 (en) 2004-01-21 2004-02-25 Novartis Ag Organic compounds
BRPI0509382A (pt) * 2004-04-02 2007-09-18 Glaxo Group Ltd processo para a preparação de um sal monocloridrato de composto, monocloridrato cristalino, processo para obter monocloridrato cristalino, método para a profilaxia ou o tratamento de uma condição clìnica em um mamìfero, uso de monocloridrato cristalino, formulação farmacêutica, e, combinação
GB0411056D0 (en) 2004-05-18 2004-06-23 Novartis Ag Organic compounds
AR049384A1 (es) 2004-05-24 2006-07-26 Glaxo Group Ltd Derivados de purina
TWI307630B (en) 2004-07-01 2009-03-21 Glaxo Group Ltd Immunoglobulins
GB0418045D0 (en) 2004-08-12 2004-09-15 Glaxo Group Ltd Compounds
KR101061850B1 (ko) 2004-09-08 2011-09-02 삼성전자주식회사 박막 트랜지스터 표시판 및 그 제조방법
GT200500281A (es) 2004-10-22 2006-04-24 Novartis Ag Compuestos organicos.
GB0424284D0 (en) 2004-11-02 2004-12-01 Novartis Ag Organic compounds
GB0426164D0 (en) 2004-11-29 2004-12-29 Novartis Ag Organic compounds
US20090124588A1 (en) * 2005-01-10 2009-05-14 Glaxo Group Limited Androstane 17-Alpha-Carbonate for Use in the Treatment of Inflammatory and Allergic Conditions
US7579335B2 (en) * 2005-01-10 2009-08-25 Glaxo Group Limited Androstane 17α-carbonate derivatives for use in the treatment of allergic and inflammatory conditions
KR20070097106A (ko) * 2005-01-11 2007-10-02 글락소 그룹 리미티드 베타-2 아드레날린성 효능제의 신나메이트 염
MY145281A (en) 2005-03-25 2012-01-13 Glaxo Group Ltd Novel compounds
GB0507577D0 (en) 2005-04-14 2005-05-18 Novartis Ag Organic compounds
GB0510390D0 (en) 2005-05-20 2005-06-29 Novartis Ag Organic compounds
GB0514809D0 (en) 2005-07-19 2005-08-24 Glaxo Group Ltd Compounds
US7910708B2 (en) 2005-10-21 2011-03-22 Novartis Ag Anti-IL13 human antibodies
KR101329112B1 (ko) 2005-11-08 2013-11-14 랜박시 래보러터리스 리미티드 (3ｒ,5ｒ)-7-〔2-(4-플루오로페닐)-5-이소프로필-3-페닐-4-〔(4-히드록시 메틸 페닐 아미노)카르보닐〕-피롤-1-일〕-3,5-디히드록시 헵탄산 헤미 칼슘염의 제조 방법
AR058109A1 (es) 2005-12-20 2008-01-23 Glaxo Group Ltd Acido 3 - (4 - {[4 -(4 -{[3 - (3, 3 - dimetil - 1 - piperidinil)propil]oxi}fenil) - 1 - piperidinil]carbonil} - 1 - naftalenil)propanoico como antagonistas de los receptotres de histamina h1/h3, composiciones farmaceuticas que los contienen y su uso en la preparacion de medicamentos para el tratamie
GB0526244D0 (en) 2005-12-22 2006-02-01 Novartis Ag Organic compounds
RU2430913C2 (ru) 2006-01-06 2011-10-10 Сепракор Инк. Циклоалкиламины в качестве ингибиторов повторного поглощения моноамина
GB0601951D0 (en) 2006-01-31 2006-03-15 Novartis Ag Organic compounds
CA2649509A1 (en) 2006-04-20 2007-11-01 Glaxo Group Limited Novel compounds
KR20080110925A (ko) 2006-04-21 2008-12-19 노파르티스 아게 아데노신 ａ２ａ 수용체 효능제로서 사용하기 위한 퓨린 유도체
AU2007253734B2 (en) 2006-05-19 2013-07-25 Dart Neuroscience (Cayman) Ltd. Phosphodiesterase 4 inhibitors for cognitive and motor rehabilitation
GB0611587D0 (en) 2006-06-12 2006-07-19 Glaxo Group Ltd Novel compounds
CL2007001829A1 (es) 2006-06-23 2008-01-25 Smithkline Beecham Corp P-toluensulfonato de n-[4-cloro-2-hidroxi-3-(piperazina-1-sulfonil)fenil]-n-(2-cloro-3-fluorofenil)urea;procedimiento de preparacion;composicion farmaceutica;combinacion farmaceutica;y uso en el tratamiento de una enfermedad mediada por la quiimioquina il-8, tales como asma y epoc.
RS53461B (en) 2006-07-05 2014-12-31 Takeda Gmbh COMBINATION OF HMG-COA REDUCTASE INHIBITOR OR SIMVASTATIN WITH PHOSPHODIESTERASE 4 INHIBITOR AS A ROFLUMILAST FOR THE TREATMENT OF INFLAMMATORY PULMONARY DISEASES
WO2008006118A2 (en) * 2006-07-07 2008-01-10 Bioassets Development Corporation Novel regimens for treating diseases and disorders
DE602007013441D1 (de) 2006-09-29 2011-05-05 Novartis Ag Pyrazolopyrimidine als pi3k-lipidkinasehemmer
CA2667962A1 (en) 2006-10-30 2008-05-08 Novartis Ag Heterocyclic compounds as antiinflammatory agents
CN101657460A (zh) * 2006-12-13 2010-02-24 基利得科学公司 用于治疗肺炎症和支气管收缩的作为抗炎性信号转导调节剂(AISTM’S)和β-激动剂的相互前药的单磷酸酯
DE602007011670D1 (de) 2007-01-10 2011-02-10 Irm Llc Verbindungen und zusammensetzungen als kanal-aktivierende proteasehemmer
PE20081889A1 (es) 2007-03-23 2009-03-05 Smithkline Beecham Corp Indol carboxamidas como inhibidores de ikk2
US20090182035A1 (en) * 2007-04-11 2009-07-16 Alcon Research, Ltd. Use of a combination of olopatadine and cilomilast to treat non-infectious rhinitis and allergic conjunctivitis
TW200902025A (en) * 2007-04-11 2009-01-16 Alcon Res Ltd Use of an inhibitor of TNF α plus an antihistamine to treat allergic rhinitis and allergic conjunctivitis
BRPI0811562A2 (pt) 2007-05-07 2014-12-09 Novartis Ag Compostos orgânicos
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
CA3089569C (en) 2007-06-04 2023-12-05 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US20100120694A1 (en) 2008-06-04 2010-05-13 Synergy Pharmaceuticals, Inc. Agonists of Guanylate Cyclase Useful for the Treatment of Gastrointestinal Disorders, Inflammation, Cancer and Other Disorders
MY148903A (en) * 2007-06-05 2013-06-14 Sanofi Aventis Di(hetero)arylclohexane derivatives, their preparation, their use and pharmaceutical compositions comprising them
US7943658B2 (en) * 2007-07-23 2011-05-17 Bristol-Myers Squibb Company Indole indane amide compounds useful as CB2 agonists and method
TW200920369A (en) * 2007-10-26 2009-05-16 Amira Pharmaceuticals Inc 5-lipoxygenase activating protein (flap) inhibitor
EP2231280B1 (en) 2007-12-10 2016-08-10 Novartis AG Amiloride-like Pyrazine-carboxamides as ENaC blockers
PL2231642T3 (pl) 2008-01-11 2014-04-30 Novartis Ag Pirymidyny jako inhibitory kinazy
MX2010012814A (es) 2008-05-23 2010-12-20 Amira Pharmaceuticals Inc Inhibidor de proteina activadora de 5-lipoxigenasa.
EP2280959B1 (en) 2008-06-05 2012-04-04 Glaxo Group Limited 4-amino-indazoles
WO2009147187A1 (en) 2008-06-05 2009-12-10 Glaxo Group Limited 4-carboxamide indazole derivatives useful as inhibitors of p13-kinases
US8236808B2 (en) 2008-06-10 2012-08-07 Novartis Ag Pyrazine derivatives as ENAC blockers
EP2321341B1 (en) 2008-07-16 2017-02-22 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase useful for the treatment of gastrointestinal, inflammation, cancer and other disorders
PT2391366E (pt) 2009-01-29 2013-02-05 Novartis Ag Benzimidazoles substituídos para o tratamento de astrocitomas
WO2010094643A1 (en) 2009-02-17 2010-08-26 Glaxo Group Limited Quinoline derivatives and their uses for rhinitis and urticaria
JP5656880B2 (ja) 2009-03-09 2015-01-21 グラクソ グループ リミテッドＧｌａｘｏ Ｇｒｏｕｐ Ｌｉｍｉｔｅｄ Ｐｉ３キナーゼの阻害剤としての４−オキサジアゾール−２−イル−インダゾール
JP2012520257A (ja) 2009-03-10 2012-09-06 グラクソ グループ リミテッド Ｉｋｋ２阻害剤としてのインドール誘導体
WO2010106016A1 (en) 2009-03-17 2010-09-23 Glaxo Group Limited Pyrimidine derivatives used as itk inhibitors
WO2010107958A1 (en) 2009-03-19 2010-09-23 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 6 (STAT6) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
JP2012520683A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いた結合組織増殖因子（ＣＴＧＦ）遺伝子発現のＲＮＡ干渉媒介性阻害
JP2012520684A (ja) 2009-03-19 2012-09-10 メルク・シャープ・エンド・ドーム・コーポレイション 低分子干渉核酸（ｓｉＮＡ）を用いたＢＴＢａｎｄＣＮＣＨｏｍｏｌｏｇｙ１（塩基性ロイシンジッパー転写因子１）（Ｂａｃｈ１）遺伝子発現のＲＮＡ干渉媒介性阻害
EP2408915A2 (en) 2009-03-19 2012-01-25 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF GATA BINDING PROTEIN 3 (GATA3) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
EP2411516A1 (en) 2009-03-27 2012-02-01 Merck Sharp&Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF APOPTOSIS SIGNAL-REGULATING KINASE 1 (ASK1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
WO2010111471A2 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. RNA INTERFERENCE MEDIATED INHIBITION OF SIGNAL TRANSDUCER AND ACTIVATOR OF TRANSCRIPTION 1 (STAT1) GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACID (siNA)
US20120022143A1 (en) 2009-03-27 2012-01-26 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Thymic Stromal Lymphopoietin (TSLP) Gene Expression Using Short Interfering Nucliec Acid (siNA)
CA2756069A1 (en) 2009-03-27 2010-09-30 Merck Sharp & Dohme Corp. Rna interference mediated inhibition of the intercellular adhesion molecule 1 (icam-1)gene expression using short interfering nucleic acid (sina)
US20120004281A1 (en) 2009-03-27 2012-01-05 Merck Sharp & Dohme Corp RNA Interference Mediated Inhibition of the Nerve Growth Factor Beta Chain (NGFB) Gene Expression Using Short Interfering Nucleic Acid (siNA)
US8399436B2 (en) 2009-04-24 2013-03-19 Glaxo Group Limited N-pyrazolyl carboxamides as CRAC channel inhibitors
EP2421834A1 (en) 2009-04-24 2012-02-29 Glaxo Group Limited Pyrazole and triazole carboxamides as crac channel inhibitors
PL2899191T3 (pl) 2009-04-30 2018-01-31 Glaxo Group Ltd Indazole podstawione oksazolem jako inhibitory kinazy PI3
US8389526B2 (en) 2009-08-07 2013-03-05 Novartis Ag 3-heteroarylmethyl-imidazo[1,2-b]pyridazin-6-yl derivatives
EP2464649A1 (en) 2009-08-12 2012-06-20 Novartis AG Heterocyclic hydrazone compounds and their uses to treat cancer and inflammation
NZ598220A (en) 2009-08-17 2014-02-28 Intellikine Llc Heterocyclic compounds and uses thereof
CA2771432A1 (en) 2009-08-20 2011-02-24 Novartis Ag Heterocyclic oxime compounds
MX2012003693A (es) * 2009-10-01 2012-04-19 Alcon Res Ltd Composiciones de olopatadine y usos de las mismas.
CA2777245A1 (en) 2009-10-22 2011-04-28 Vertex Pharmaceuticals Incorporated Compositions for treatment of cystic fibrosis and other chronic diseases
WO2011067365A1 (en) 2009-12-03 2011-06-09 Glaxo Group Limited Benzpyrazole derivatives as inhibitors of p13 kinases
EP2507231A1 (en) 2009-12-03 2012-10-10 Glaxo Group Limited Indazole derivatives as pi 3 - kinase inhibitors
US20120238559A1 (en) 2009-12-03 2012-09-20 Glaxo Group Limited Novel compounds
EP3020393B1 (en) 2009-12-16 2020-10-07 3M Innovative Properties Company Formulations and methods for controlling mdi particle size delivery
WO2011110575A1 (en) 2010-03-11 2011-09-15 Glaxo Group Limited Derivatives of 2-[2-(benzo- or pyrido-) thiazolylamino]-6-aminopyridine, useful in the treatment of respiratoric, allergic or inflammatory diseases
US8247436B2 (en) 2010-03-19 2012-08-21 Novartis Ag Pyridine and pyrazine derivative for the treatment of CF
GB201007203D0 (en) 2010-04-29 2010-06-16 Glaxo Group Ltd Novel compounds
EP2613781B1 (en) 2010-09-08 2016-08-24 GlaxoSmithKline Intellectual Property Development Limited Indazole derivatives for use in the treatment of influenza virus infection
PL2614058T3 (pl) 2010-09-08 2015-12-31 Glaxosmithkline Ip Dev Ltd Polimorfy i sole n-[5-[4-(5-{[(2r,6s)-2,6-dimetylo-4-morfolinylo]-metylo}-1,3-oksazol-2-ilo)-1h-indazol-6-ilo]-2-(metyloksy)-3-pirydynylo]metanosulfonamidu
WO2012034095A1 (en) 2010-09-09 2012-03-15 Irm Llc Compounds and compositions as trk inhibitors
UY33597A (es) 2010-09-09 2012-04-30 Irm Llc Compuestos y composiciones como inhibidores de la trk
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
US8372845B2 (en) 2010-09-17 2013-02-12 Novartis Ag Pyrazine derivatives as enac blockers
WO2012035055A1 (en) 2010-09-17 2012-03-22 Glaxo Group Limited Novel compounds
JP2013544794A (ja) 2010-10-21 2013-12-19 グラクソ グループ リミテッド アレルギー性障害、炎症性障害及び免疫障害に作用するピラゾール化合物
ES2532213T3 (es) 2010-10-21 2015-03-25 Glaxo Group Limited Compuestos de pirazol que actúan contra afecciones alérgicas, inmunitarias e inflamatorias
GB201018124D0 (en) 2010-10-27 2010-12-08 Glaxo Group Ltd Polymorphs and salts
JP2014505088A (ja) 2011-02-10 2014-02-27 ノバルティス アーゲー Ｃ−ＭＥＴチロシンキナーゼ阻害剤としての［１，２，４］トリアゾロ［４，３−ｂ］ピリダジン化合物
JP5808826B2 (ja) 2011-02-23 2015-11-10 インテリカイン， エルエルシー 複素環化合物およびその使用
US9102671B2 (en) 2011-02-25 2015-08-11 Novartis Ag Compounds and compositions as TRK inhibitors
CN108676076A (zh) 2011-03-01 2018-10-19 辛纳吉制药公司 制备鸟苷酸环化酶c激动剂的方法
GB201104153D0 (en) 2011-03-11 2011-04-27 Glaxo Group Ltd Novel compounds
JP2014507458A (ja) 2011-03-11 2014-03-27 グラクソ グループ リミテッド Ｓｙｋインヒビターとしてのピリド［３，４−Ｂ］ピラジン誘導体
UY34305A (es) 2011-09-01 2013-04-30 Novartis Ag Derivados de heterociclos bicíclicos para el tratamiento de la hipertensión arterial pulmonar
UY34329A (es) 2011-09-15 2013-04-30 Novartis Ag Compuestos de triazolopiridina
WO2013038373A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
EP2755652B1 (en) 2011-09-16 2021-06-02 Novartis AG N-substituted heterocyclyl carboxamides
WO2013038381A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine/pyrazine amide derivatives
WO2013038378A1 (en) 2011-09-16 2013-03-21 Novartis Ag Pyridine amide derivatives
ES2558457T3 (es) 2011-09-16 2016-02-04 Novartis Ag Compuestos heterocíclicos para el tratamiento de fibrosis quística
US9174994B2 (en) 2011-11-23 2015-11-03 Intellikine, Llc Enhanced treatment regimens using mTor inhibitors
WO2013084182A1 (en) 2011-12-08 2013-06-13 Glenmark Pharmaceuticals S.A. Pharmaceutical composition that includes a pde4 enzyme inhibitor and an analgesic agent
US8809340B2 (en) 2012-03-19 2014-08-19 Novartis Ag Crystalline form
CN104245701A (zh) 2012-04-03 2014-12-24 诺华有限公司 有酪氨酸激酶抑制剂的组合产品和其应用
JP6499591B2 (ja) 2013-02-25 2019-04-10 シナジー ファーマシューティカルズ インコーポレイテッド 結腸洗浄において用いるためのグアニル酸シクラーゼ受容体アゴニスト
US9073921B2 (en) 2013-03-01 2015-07-07 Novartis Ag Salt forms of bicyclic heterocyclic derivatives
JP2016514670A (ja) 2013-03-15 2016-05-23 シナジー ファーマシューティカルズ インコーポレイテッド 他の薬物と組み合わせたグアニル酸シクラーゼ受容体アゴニスト
EP2970384A1 (en) 2013-03-15 2016-01-20 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
EP2968340A4 (en) 2013-03-15 2016-08-10 Intellikine Llc COMBINING KINASE INHIBITORS AND USES THEREOF
RS65632B1 (sr) 2013-06-05 2024-07-31 Bausch Health Ireland Ltd Ultra-prečišćeni agonisti guanilat-ciklaze c, postupak njihove pripreme i upotrebe
WO2015021358A2 (en) 2013-08-09 2015-02-12 Dominique Charmot Compounds and methods for inhibiting phosphate transport
SG11201600707QA (en) 2013-09-22 2016-02-26 Calitor Sciences Llc Substituted aminopyrimidine compounds and methods of use
JP2016537327A (ja) 2013-10-17 2016-12-01 グラクソスミスクライン、インテレクチュアル、プロパティー、ディベロップメント、リミテッドＧｌａｘｏｓｍｉｔｈｋｌｉｎｅ Ｉｎｔｅｌｌｅｃｔｕａｌ Ｐｒｏｐｅｒｔｙ Ｄｅｖｅｌｏｐｍｅｎｔ Ｌｉｍｉｔｅｄ 呼吸器疾患の治療のためのｐｉ３ｋ阻害剤
CA2925064A1 (en) 2013-10-17 2015-04-23 Glaxosmithkline Intellectual Property Development Limited Pi3k inhibitor for treatment of respiratory disease
TW201605450A (zh) 2013-12-03 2016-02-16 諾華公司 Ｍｄｍ２抑制劑與ＢＲＡＦ抑制劑之組合及其用途
JP6517319B2 (ja) 2014-03-28 2019-05-22 キャリター・サイエンシーズ・リミテッド・ライアビリティ・カンパニーＣａｌｉｔｏｒ Ｓｃｉｅｎｃｅｓ， Ｌｌｃ 置換されたヘテロアリール化合物および使用方法
BR112016023967A2 (pt) 2014-04-24 2017-08-15 Novartis Ag derivados de pirazina como inibidores de fosfatidilinositol 3-cinase
WO2015162456A1 (en) 2014-04-24 2015-10-29 Novartis Ag Amino pyridine derivatives as phosphatidylinositol 3-kinase inhibitors
JP6433509B2 (ja) 2014-04-24 2018-12-05 ノバルティス アーゲー ホスファチジルイノシトール３−キナーゼ阻害薬としてのアミノピラジン誘導体
EA201692111A1 (ru) 2014-05-12 2017-08-31 Глаксосмитклайн Интеллекчуал Проперти (№ 2) Лимитед Фармацевтические композиции, содержащие данириксин, для лечения инфекционных заболеваний
WO2016011658A1 (en) 2014-07-25 2016-01-28 Novartis Ag Combination therapy
KR20170036037A (ko) 2014-07-31 2017-03-31 노파르티스 아게 조합 요법
WO2017044434A1 (en) 2015-09-11 2017-03-16 Sunshine Lake Pharma Co., Ltd. Substituted heteroaryl compounds and methods of use
EP3165224A1 (en) 2015-11-09 2017-05-10 Albert-Ludwigs-Universität Freiburg Use of pde4 inhibitors for the prophylaxis and/or therapy of dyslipoproteinaemia and related disorders
WO2017089347A1 (en) 2015-11-25 2017-06-01 Inserm (Institut National De La Sante Et De La Recherche Medicale) Methods and pharmaceutical compositions for the treatment of braf inhibitor resistant melanomas
GB201602527D0 (en) 2016-02-12 2016-03-30 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3497100A1 (en) 2016-08-08 2019-06-19 GlaxoSmithKline Intellectual Property Development Limited Chemical compounds
US20190307975A1 (en) 2016-11-21 2019-10-10 Lupin Inc. Medicament dispenser
GB201706102D0 (en) 2017-04-18 2017-05-31 Glaxosmithkline Ip Dev Ltd Chemical compounds
GB201712081D0 (en) 2017-07-27 2017-09-13 Glaxosmithkline Ip Dev Ltd Chemical compounds
EP3710006A4 (en) 2017-11-19 2021-09-01 Sunshine Lake Pharma Co., Ltd. SUBSTITUTED HETEROARYL COMPOUNDS AND THEIR METHODS OF USE
US10751339B2 (en) 2018-01-20 2020-08-25 Sunshine Lake Pharma Co., Ltd. Substituted aminopyrimidine compounds and methods of use
US20210085897A1 (en) 2018-04-06 2021-03-25 Lupin Inc. Medicament dispenser
TWI845505B (zh) * 2018-04-11 2024-06-21 日商三菱瓦斯化學股份有限公司 1,4-環己烷二甲酸衍生物、1,4-二氰基環己烷、及1,4-雙(胺甲基)環己烷之製造方法
WO2020058823A1 (en) 2018-09-17 2020-03-26 Lupin, Inc. Dose indicator assembly for a medicament dispenser
JP2022533251A (ja) 2019-05-21 2022-07-21 アルデリックス， インコーポレイテッド 患者において血清リン酸塩を低下させるための組み合わせ
US20200383960A1 (en) 2019-06-10 2020-12-10 Novartis Ag Pyridine and Pyrazine derivative for the Treatment of CF, COPD, and Bronchiectasis
JP2022547427A (ja) 2019-08-28 2022-11-14 ノバルティス アーゲー 置換１，３－フェニルヘテロアリール誘導体及び疾患の治療におけるその使用
CA3176877A1 (en) 2020-03-25 2021-09-30 Lupin Inc. Multi-carrier medicament dispensers
EP4125919A1 (en) 2020-03-26 2023-02-08 GlaxoSmithKline Intellectual Property Development Limited Cathepsin inhibitors for preventing or treating viral infections
MX2023000955A (es) 2020-07-23 2023-04-26 Lupin Inc Conjuntos contadores de dosis para dispensadores de medicamentos.

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795757A (en) * 1984-09-04 1989-01-03 Rorer Pharmaceutical Corporation Bisarylamines

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3862239A (en) * 1967-08-22 1975-01-21 Ortho Pharma Corp Aryl substituted cyclohexenecarbinols
US3979444A (en) * 1974-05-28 1976-09-07 The Upjohn Company 4-Arylcyclohexylamines
JP3333510B2 (ja) * 1991-10-02 2002-10-15 スミスクライン・ビーチャム・コーポレイション 抗アレルギー、抗炎症および腫瘍壊死因子抑制活性を有するシクロペンタンおよびシクロペンテン誘導体
WO1993019750A1 (en) * 1992-04-02 1993-10-14 Smithkline Beecham Corporation Compounds useful for treating allergic or inflammatory diseases
DE69328778T2 (de) * 1992-04-02 2000-11-23 Smithkline Beecham Corp., Philadelphia Verbindungen für die behandlung von entzündlichen erkrankungen und zur hemmung der produktion von tumornekrosefaktor
EP0633771A4 (en) * 1992-04-02 1995-02-22 Smithkline Beecham Corporation Compounds.

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4795757A (en) * 1984-09-04 1989-01-03 Rorer Pharmaceutical Corporation Bisarylamines

Also Published As

Publication number Publication date
MX9301943A (es) 1994-08-31
SK279958B6 (sk) 1999-06-11
US5552438A (en) 1996-09-03
WO1993019749A1 (en) 1993-10-14
CN1092406A (zh) 1994-09-21
AU3791093A (en) 1993-11-08
CZ283425B6 (cs) 1998-04-15
BG62235B1 (bg) 1999-06-30
SI9300169B (sl) 2008-04-30
CA2133439C (en) 2005-07-26
CZ239794A3 (en) 1995-05-17
HU225869B1 (en) 2007-11-28
AU677776B2 (en) 1997-05-08
NO943663L (no) 1994-11-15
CN1066436C (zh) 2001-05-30
US5602157A (en) 1997-02-11
NO943663D0 (no) 1994-09-30
EP0633776A4 (sl) 1995-01-25
SK117194A3 (en) 1995-06-07
AP516A (en) 1996-08-23
FI944549A (fi) 1994-11-30
IL105221A (en) 2000-01-31
HU9402817D0 (en) 1995-01-30
HUT70523A (en) 1995-10-30
NZ251092A (en) 1996-12-20
US5643946A (en) 1997-07-01
AP9300508A0 (en) 1993-04-30
AP9600794A0 (en) 1996-04-30
IL105221A0 (en) 1994-08-26
BG99080A (bg) 1995-08-28
GR3036347T3 (en) 2001-11-30
FI944549A0 (fi) 1994-09-30
EP0633776A1 (en) 1995-01-18
SI9300169A (en) 1993-12-31
EP0633776B1 (en) 2001-05-09
CA2133439A1 (en) 1993-10-14
US5614540A (en) 1997-03-25
NO303116B1 (no) 1998-06-02

Similar Documents

Publication Publication Date Title
AP519A (en) Pharmaceutical compositions containing novel compounds and their use in treating allergic and inflamatory diseases.
US5602173A (en) Compounds useful for treating allergic and inflammatory diseases
AU708544B2 (en) Compounds useful for treating allergic or inflammatory diseases
EP0636026B1 (en) Compounds useful for treating inflammatory diseases and inhibiting production of tumor necrosis factor
US6300372B1 (en) 3-Cyano-3-(3,4-disubstituted) phenylcyclohexyl-1-carboxylates
WO1993019720A2 (en) Compounds
WO1995009836A1 (en) Cyanocyclohexane compounds, compositions, and uses thereof
WO1995009623A1 (en) Anti-allergic, anti-inflammatory compounds, compositions and uses
EP0722322A1 (en) Compounds, compositions and treatment of allergies and inflammation therewith
AU705566B2 (en) A method for treating allergic and inflammatory diseases and for inhibiting the production of Tumor Necrosis Factor
WO1995009837A1 (en) Cyano compounds
WO1996020156A1 (en) 3,3-(disubstituted)cyclohexan-1-carboxylate dimers and related compounds
AU4527696A (en) 3,3-(disubstituted)cyclohexan-1-one monomers and related compounds
WO1996019978A1 (en) 1,3,3-(trisubstituted)cyclohex-1-ene dimers and related compounds